BioMark Diagnostics, Inc.: BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy

Vancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy t...